Results 41 to 50 of about 15,994,939 (300)

Co-receptor CD8-mediated modulation of T-cell receptor functional sensitivity and epitope recognition degeneracy [PDF]

, 2013
The interaction between T-cell receptors (TCRs) and peptide epitopes is highly degenerate: a TCR is capable of interacting productively with a wide range of different peptide ligands, involving not only cross-reactivity proper (similar epitopes elicit ...
Linda Wooldridge, van den Berg, Hugo Antonius, Dockree, Tamsin, Van Den Berg, Hugo A, Berg, Hugo van den, Linda eWooldridge, Williams, Tamsin, Barbara Szomolay, Tamsin eWlliams, Tamsin Williams, Szomolay, Barbara, Hugo Antonius Van Den Berg, Barbara eSzomolay, Wooldridge, Linda   +13 more
core   +1 more source

Developing T-cell therapies for lymphoma without receptor engineering

Blood Advances, 2017
: T-cell therapy has emerged from the bench for the treatment of patients with lymphoma. Responses to T-cell therapeutics are regulated by multiple factors, including the patient's immune system status and disease stage.
Melanie Grant, Catherine M. Bollard
doaj   +1 more source

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

Nature, 2019
Chimeric antigen receptors (CARs) are synthetic antigen receptors that reprogram T cell specificity, function and persistence1. Patient-derived CAR T cells have demonstrated remarkable efficacy against a range of B-cell malignancies1–3, and the results ...
Mohamad Hamieh, A. Dobrin, Annalisa Cabriolu, S. V. D. van der Stegen, Theodoros Giavridis, J. Mansilla-Soto, Justin Eyquem, Ze-Guo Zhao, Benjamin Whitlock, Matthew M. Miele, Zhuoning Li, K. Cunanan, M. Huse, R. Hendrickson, Xiu-Yan Wang, I. Rivière, M. Sadelain   +16 more
semanticscholar   +1 more source

Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application

Haematologica, 2008
Background Donor lymphocyte infusion is an effective form of adoptive immunotherapy for hematologic malignancies after allogeneic stem cell transplantation.
Marieke Griffioen, H.M. Esther van Egmond, Helen Barnby-Porritt, Menno A.W.G. van der Hoorn, Renate S. Hagedoorn, Michel G.D. Kester, Nikolai Schwabe, Roel Willemze, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk   +9 more
doaj   +1 more source

Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing

PLoS ONE, 2015
Monitoring antigen-specific T cells is critical for the study of immune responses and development of biomarkers and immunotherapeutics. We developed a novel multiplex assay that combines conventional immune monitoring techniques and immune receptor ...
M. Klinger, F. Pépin, J. Wilkins, Thomas Asbury, T. Wittkop, Jianbiao Zheng, M. Moorhead, M. Faham   +7 more
semanticscholar   +1 more source

Gene modification strategies for next-generation CAR T cells against solid cancers

Journal of Hematology & Oncology, 2020
Immunotherapies have become the backbone of cancer treatment. Among them, chimeric antigen receptor (CAR) T cells have demonstrated great success in the treatment of hematological malignancies.
Yonggui Tian, Yilu Li, Yupei Shao, Yi Zhang   +3 more
doaj   +1 more source

CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19

Hematology/Oncology and Stem Cell Therapy, 2022
Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived from a high-specificity monoclonal antibody that can target surface molecules on tumor cells.
Yenny M. Vanegas, Razan Mohty, Martha E. Gadd, Yan Luo, Mahmoud Aljurf, Hong Qin, Mohamed A. Kharfan-Dabaja   +6 more
doaj   +1 more source

Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting

Cancer Cell, 2019
Summary Many potential targets for CAR-T cells in solid tumors are expressed in some normal tissues, raising concern for off-tumor toxicity. Following lymphodepletion, CAR-T cells targeting the tumor-associated antigen ROR1 lysed tumors in mice but ...
S. Srivastava, A. Salter, D. Liggitt, Sushma Yechan-Gunja, Megha Sarvothama, Kirsten Cooper, K. Smythe, Jarrod A. Dudakov, R. Pierce, C. Rader, S. Riddell   +10 more
semanticscholar   +1 more source

T-Cell activation: a queuing theory analysis at low agonist density [PDF]

, 2006
We analyze a simple linear triggering model of the T-cell receptor (TCR) within the framework of queuing theory, in which TCRs enter the queue upon full activation and exit by downregulation.
Wedagedera, J.R., Burroughs, N.J., Burroughs, Nigel John, Wedagedera, J. R.   +3 more
core   +1 more source

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

Nature Communications, 2019
T cells expressing CD19-targeting chimeric antigen receptors (CARs) reveal high efficacy in the treatment of B cell malignancies. Here, we report that T cell receptor fusion constructs (TRuCs) comprising an antibody-based binding domain fused to T cell ...
P. Baeuerle, Jian Ding, E. Patel, N. Thorausch, H. Horton, Jessica J. Gierut, Irene Scarfò, Rashmi Choudhary, O. Kiner, J. Krishnamurthy, B. Le, A. Morath, G. Christian Baldeviano, Justin Quinn, P. Tavares, Q. Wei, S. Weiler, Marcela V. Maus, D. Getts, Wolfgang W. A. Schamel, R. Hofmeister   +20 more
semanticscholar   +1 more source